Practical approaches to the use of markers of biochemical hyperandrogenism in women
Literature review
DOI:
https://doi.org/10.18370/2309-4117.2022.63.25-33Keywords:
testosterone, sex steroid-binding globulin, androstenedione, dehydroepiandrosterone sulfate, affinityAbstract
Hyperandrogenism (HA) remains an actual problem that raises a large number of questions, in particular, in cases of discrepancy between the clinical signs of HA and biochemical parameters. This review includes an analysis of recent studies of androgen synthesis and metabolism in healthy women of reproductive age; management of pathologies accompanied by HA; as well as contemporary approaches to the principles of prescribing and evaluating the results of the main available markers of biochemical HA.
There are сoncepts of clinical and biochemical HA. Biochemical HA is an increase in the levels of various circulating androgens. The concept of clinical HA includes hirsutism as assessed by the modified Ferriman–Gallwey scale. The most common causes of HA include polycystic ovary syndrome, non-classical forms of congenital adrenal hyperplasia, other endocrine disorders. It is necessary to carry out a differential diagnosis of these conditions with more rare causes as a primarily tumor pathology. The choice and evaluation of laboratory markers of biochemical HA should be made taking into account clinical data such as puberty history, anovulation, polycystic ovarian morphotype, obesity; presence and degree of hirsutism and/or other androgen-associated dermatopathies, the characteristics of the course of clinical HA (sudden onset, rapid progression), presence of other endocrinopathies, liver and kidney dysfunction; diabetes mellitus.
The objectives of the laboratory assessment of HA are determination of HA severity; determination of the source of excess androgen synthesis (ovaries, adrenal glands); assessment of the free fraction of circulating active androgens; in some cases, assessment of the formation of active androgens in the skin. The following indicators are used to solve the tasks in laboratory diagnostics: total testosterone, free testosterone, free androgen index, androstenedione, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, dihydrotestosterone. A comprehensive assessment of these indicators allows not only assessing the presence of HA and its severity, but also the nature of its leading and secondary components, which determine the presence and prognosis of metabolic risks and allow individualizing therapeutic approaches.
References
- Barth, J.H., Field, H.P., Yasmin, E., Balen, A. “Definition of hyperandrogenism.” Curr Manag Polycystic Ovary Syndr 1 (2010): 117–24. DOI: 10.1017/CBO9781107478343.012
- Lizneva, D., Gavrilova-Jordan, L., Walker, W., Azziz, R. “Androgen excess: Investigations and management.” Best Pract Res Clin Obstet Gynaecol 37 (2016): 98–118. DOI: 10.1016/j.bpobgyn.2016.05.003
- Rao, P., Bhide, P. “Controversies in the diagnosis of polycystic ovary syndrome.” Ther Adv Reprod Heal 14 (2020): 2633494120913032. DOI: 10.1177/2633494120913032
- Yildiz, B.O., Bolour, S., Woods, K., et al. “Visually scoring hirsutism.” Hum Reprod Update 16.1 (2010): 51–64. DOI: 10.1093/HUMUPD/DMP024
- Martin, K.A., Rox Anderson, R., Jeffrey Chang, R., et al. “Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 103.4 (2018): 1233–57. DOI: 10.1210/JC.2018-00241
- Carmina, E., Dreno, B., Lucky, W.A., et al. “Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.” J Endocr Soc 6.3 (2022). DOI: 10.1210/JENDSO/BVAC003
- Carmina, E., Azziz, R., Bergfeld, W., et al. “Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.” J Clin Endocrinol Metab 104.7 (2019): 2875–91. DOI: 10.1210/jc.2018-02548
- Carmina, E., Rosato, F., Jannì, A., et al. “Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism.” J Clin Endocrinol Metab 91.1 (2006): 2–6. DOI: 10.1210/JC.2005-1457
- Dubey, P., Reddy, S.Y., Alvarado, L., et al. “Prevalence of at-risk hyperandrogenism by age and race/ethnicity among females in the United States using NHANES III.” Eur J Obstet Gynecol Reprod Biol 260 (2021): 189–97. DOI: 10.1016/J.EJOGRB.2021.03.033
- Teede, H.J., Misso, M.L., Costello, M.F., et al. “Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Hum Reprod 33.9 (2018): 1602–18. DOI: 10.1093/humrep/dey256
- Azziz, R., Carmina, E., Chen, Z., et al. “Polycystic ovary syndrome.” Nat Rev Dis Primers 2 (2016): 1–18. DOI: 10.1038/nrdp.2016.57
- Bozdag, G., Mumusoglu, S., Zengin, D., et al. “The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod 31.12 (2016): 2841–55. DOI: 10.1093/HUMREP/DEW218
- Sharma, A., Welt, C.K. “Practical Approach to Hyperandrogenism in Women.” Med Clin 105.6 (2021): 1099–116. DOI: 10.1016/J.MCNA.2021.06.008
- Carmina, E. “Cutaneous manifestations of polycystic ovary syndrome.” Curr Opin Endocr Metab Res. 12 (2020): 49–52. DOI: 10.1016/J.COEMR.2020.02.015
- Moran, C., Arriaga, M., Arechavaleta-Velasco, F., Moran, S. “Adrenal Androgen Excess and Body Mass Index in Polycystic Ovary Syndrome.” J Clin Endocrinol Metab 100.3 (2015): 942–50. DOI: 10.1210/JC.2014-2569
- Sanchez-Garrido, M.A., Tena-Sempere, M. “Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.” Mol Metab 35 (2020): 100937. DOI: 10.1016/J.MOLMET.2020.01.001
- Luque-Ramírez, M., Escobar-Morreale, F.H. “Adrenal Hyperandrogenism and Polycystic Ovary Syndrome.” Curr Pharm Des 22.36 (2016): 5588–5602. DOI: 10.2174/1381612822666160720150625
- Bianchi, V.E., Bresciani, E., Meanti, R., et al. “The role of androgens in women’s health and wellbeing.” Pharmacol Res 171 (2021): 105758. DOI: 10.1016/J.PHRS.2021.105758
- Schiffer, L., Arlt, W., Storbeck, K.H. “Intracrine androgen biosynthesis, metabolism and action revisited.” Mol Cell Endocrinol 465 (2018): 4–26. DOI: 10.1016/J.MCE.2017.08.016
- Bienenfeld, A., Azarchi, S., Lo Sicco, K., et al. “Androgens in Women: Androgen mediated skin disease and patient evaluation (Part I).” J Am Acad Dermatol (2018) Oct 10. DOI: 10.1016/J.JAAD.2018.08.062
- Walters, K.A., Handelsman, D.J. “Role of androgens in the ovary.” Mol Cell Endocrinol 465 (2018): 36–47. DOI: 10.1016/J.MCE.2017.06.026
- Qu, X., Donnelly, R. “Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome.” Int J Mol Sci 21 (2020): 8191. DOI: 10.3390/IJMS21218191
- Dunn, J.F., Nisula, B.C., Rodbard, D. “Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.” J Clin Endocrinol Metab 53.1 (1981): 58–68. DOI: 10.1210/JCEM-53-1-58
- Dumoulin, S.C., Perret, B.P., Bennet, A.P., Caron, P.J. “Opposite effects of thyroid hormones on binding proteins for steroid hormones (sex hormone-binding globulin and corticosteroid-binding globulin) in humans.” Eur J Endocrinol 132.5 (1995): 594–8. DOI: 10.1530/EJE.0.1320594
- Skałba, P., Zieba, M., Olejek, A. “Testosterone and SHBG levels in blood serum in women with anorexia nervosa.” Wiad Lek 54.9–10 (2001): 532–6.
- Miller, K.K., Lawson, E.A., Mathur, V., et al. “Androgens in Women with Anorexia Nervosa and Normal-Weight Women with Hypothalamic Amenorrhea.” J Clin Endocrinol Metab 92.4 (2007): 1334–9. DOI: 10.1210/JC.2006-2501
- Pasquali, R., Vicennati, V., Bertazzo, D., et al. “Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status.” Metabolism 46.1 (1997): 5–9. DOI: 10.1016/S0026-0495(97)90159-1
- Wei, S., Schmidt, M.D., Dwyer, T., et al. “Obesity and Menstrual Irregularity: Associations With SHBG, Testosterone, and Insulin.” Obesity 17.5 (2009): 1070–6. DOI: 10.1038/OBY.2008.641
- Slominski, A.T., Manna, P.R., Tuckey, R.C. “On the role of skin in the regulation of local and systemic steroidogenic activities.” Steroids 103 (2015): 72–88. DOI: 10.1016/j.steroids.2015.04.006
- Zouboulis, C.C., Chen, W.C., Thornton, M.J., et al. “Sexual hormones in human skin.” Horm Metab Res 39.2 (2007): 85–95. DOI: 10.1055/s-2007-961807
- Slominski, A.T., Zmijewski, M.A., Zbytek, B., et al. “Key Role of CRF in the Skin Stress Response System.” Endocr Rev 34.6 (2013): 827–84. DOI: 10.1210/ER.2012-1092
- Wagner, I.V., Savchuk, I., Sahlin, L., et al. “De Novo and Depot-Specific Androgen Production in Human Adipose Tissue: A Source of Hyperandrogenism in Women with Obesity.” Obes Facts 15.2 (2022): 281–91. DOI: 10.1159/000521571
- Lösel, R.M., Falkenstein, E., Feuring, M., et al. “Nongenomic steroid action: Controversies, questions, and answers.” Physiol Rev 83.3 (2003): 965–1016. DOI: 10.1152/physrev.00003.2003
- Heinlein, C.A., Chang, C. “The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions.” Mol Endocrinol 16.10 (2002): 2181–7. DOI: 10.1210/ME.2002-0070
- Hodgson, T.K., Braunstein, G.D. “Physiological Effects of Androgens in Women.” Androg Excess Disord Women (2006) Nov 7: 49–62. DOI: 10.1007/978-1-59745-179-6_4
- Escobar-Morreale, H.F., Carmina, E., Dewailly, D., et al. “Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.” Hum Reprod Update 18.2 (2012): 146–70. DOI: 10.1093/HUMUPD/DMR042
- Pasch, L., He, S.Y., Huddleston, H., et al. “Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression.” JAMA Dermatology 152.7 (2016): 783–8. DOI: 10.1001/JAMADERMATOL.2016.0358
- Azziz, R., Carmina, E., Sawaya, M.E. “Idiopathic Hirsutism.” Endocr Rev 21.4 (2000): 347–62. DOI: 10.1210/EDRV.21.4.0401
- Amiri, M., Fallahzadeh, A., Sheidaei, A., et al. “Prevalence of idiopathic hirsutism: A systematic review and meta-analysis.” J Cosmet Dermatol (2021). DOI: 10.1111/JOCD.14313
- Trüeb, R.M. “Causes and Management of Hypertrichosis.” Am J Clin Dermatology 3.9 (2002): 617–27. DOI: 10.2165/00128071-200203090-00004
- Carmina, E., Azziz, R., Bergfeld, W., et al. “Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee.” J Clin Endocrinol Metab 104.7 (2019): 2875–91. DOI: 10.1210/jc.2018-02548
- Uysal, G., Sahin, Y., Unluhizarci, K., et al. “Is acne a sign of androgen excess disorder or not?” Eur J Obstet Gynecol Reprod Biol 211 (2017): 21–5. DOI: 10.1016/J.EJOGRB.2017.01.054
- Rocha, M.A., Bagatin, E. “Adult-onset acne: Prevalence, impact, and management challenges.” Clin Cosmet Investig Dermatol 11 (2018): 59–69. DOI: 10.2147/CCID.S137794
- Kircik, L.H. “Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist.” Expert Opin Pharmacother 22.13 (2021): 1801–6. DOI: 10.1080/14656566.2021.1918100
- Ding, T., Hardiman, P.J., Petersen, I., et al. “The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis.” Oncotarget 8.56 (2017): 96351. DOI: 10.18632/ONCOTARGET.19180
- O’Reilly, M.W., Taylor, A.E., Crabtree, N.J., et al. “Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione.” J Clin Endocrinol Metab 99.3 (2014): 1027–36. DOI: 10.1210/JC.2013-3399
- Lerchbaum, E., Schwetz, V., Rabe, T., et al. “Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.” PLoS One 9.10 (2014): e108263. DOI: 10.1371/JOURNAL.PONE.0108263
- Yildiz, B.O., Azziz, R. “The adrenal and polycystic ovary syndrome.” Rev Endocr Metab Disord 8.4 (2007): 331–42. DOI: 10.1007/s11154-007-9054-0
- Goodarzi, M.O., Carmina, E., Azziz, R. “DHEA, DHEAS and PCOS.” J Steroid Biochem Mol Biol 145 (2015): 213–25. DOI: 10.1016/J.JSBMB.2014.06.003
- Münzker, J., Hofer, D., Trummer, C., et al. “Testosterone to Dihydrotestosterone Ratio as a New Biomarker for an Adverse Metabolic Phenotype in the Polycystic Ovary Syndrome.” J Clin Endocrinol Metab 100.2 (2015): 653–60. DOI: 10.1210/JC.2014-2523
- Speiser, P.W., Arlt, W., Auchus, R.J., et al. “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society. Clinical Practice Guideline.” J Clin Endocrinol Metab 103.11 (2018): 4043–88. DOI: 10.1210/jc.2018-01865
- Speiser, P.W., Azziz, R., Baskin, L.S., et al. “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 95.9 (2010): 4133–60. DOI: 10.1210/jc.2009-2631
- Witchel, S.F., Azziz, R. “Nonclassic Congenital Adrenal Hyperplasia.” Int J Pediatr Endocrinol 1 (2010): 1–11. DOI: 10.1155/2010/625105
- Jha, S., Turcu, A.F. “Nonclassic Congenital Adrenal Hyperplasia: What Do Endocrinologists Need to Know?” Endocrinol Metab Clin 50.1 (2021): 151–65. DOI: 10.1016/J.ECL.2020.10.008
- Papadakis, G., Kandaraki, E.A., Tseniklidi, E., et al. “Polycystic ovary syndrome and NC-CAH: Distinct characteristics and common findings. A systematic review.” Front Endocrinol (Lausanne) 10 (2019): 388. DOI: 10.3389/FENDO.2019.00388
- Hannah-Shmouni, F., Morissette, R., Sinaii, N., et al. “Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.” Genet Med 19.11 (2017): 1276–9. DOI: 10.1038/GIM.2017.46
- Carmina, E., Dewailly, D., Escobar-Morreale, H.F., et al. “Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.” Hum Reprod Update. 23.5 (2017): 580–99. DOI: 10.1093/HUMUPD/DMX014
- Bidet, M., Bellanné-Chantelot, C., Galand-Portier, M.B., et al. “Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.” J Clin Endocrinol Metab 95.3 (2010): 1182–90. DOI: 10.1210/JC.2009-1383
- Macut, D., Ilić, D., Mitrović Jovanović, A., Bjekić-Macut, J. “Androgen-Secreting Ovarian Tumors.” Frontiers Horm Res 53 (2019): 100–7. DOI: 10.1159/000494906
- Pasquali, R., Pignatelli, D. “Hyperandrogenism in women: beyond polycystic ovary syndrome.” Front Horm Res 53 (2019): I–0. DOI: 10.1159/000494912
- Libé, R., Coste, J., Guignat, L., et al. “Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome.” Eur J Endocrinol 163.1 (2010): 129–38. DOI: 10.1530/EJE-10-0195
- Terzolo, M., Osella, G., Alì, A., et al. “Different patterns of steroid secretion in patients with adrenal incidentaloma.” J Clin Endocrinol Metab 81.2 (1996): 740–4. DOI: 10.1210/JCEM.81.2.8636297
- Ramkumar, S., Jyotsna, V.P., Mallick, S., et al. “Bilateral thecoma presenting as premenopausal hirsutism: Laproscopic removal.” Indian J Endocrinol Metab 17.3 (2013): S662. DOI: 10.4103/2230-8210.123561
- Iravanloo, G., Nozarian, Z., Sarrafpour, B., Motahhary, P. “Sclerosing stromal tumor of the ovary.” Obstet Gynecol Sci 57.5 (2014): 405. DOI: 10.5468/OGS.2014.57.5.405
- Meczekalski, B., Szeliga, A., Maciejewska-Jeske, M., et al. “Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol 37.8 (2021): 677–82. DOI: 10.1080/09513590.2021.1903419
- Pivonello, R., Isidori, A.M., De Martino, M.C., et al. “Complications of Cushing’s syndrome: state of the art.” Lancet Diabetes Endocrinol 4.7 (2016): 611–29. DOI: 10.1016/S2213-8587(16)00086-3
- Shlomo Melmed Acromegaly. Pituitary (2017): 423–66. DOI: 10.1016/B978-0-12-804169-7.00015-5
- Delcour, C., Robin, G., Young, J., Dewailly, D. “PCOS and Hyperprolactinemia: what do we know in 2019?” Clin Med Insights Reprod Heal 13 (2019): 117955811987192. DOI: 10.1177/1179558119871921
- Herzog, A.G. “Disorders of reproduction in patients with epilepsy.” Zeitschrift für Epileptol 28.4 (2015): 254–63. DOI: 10.1007/s10309-015-0012-7
- Markopoulos, M.C., Kassi, E., Alexandraki, K.I., et al. “Hyperandrogenism after menopause.” Eur J Endocrinol 172.2 (2015): R79–91. DOI: 10.1530/EJE-14-0468
- Davis, S.R., Baber, R., Panay, N., et al. “Global Consensus Position Statement on the Use of Testosterone Therapy for Women.” J Clin Endocrinol Metab 104.10 (2019): 4660–6. DOI: 10.1210/JC.2019-01603
- Rosner, W., Auchus, R.J., Azziz, R., et al. “Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement.” J Clin Endocrinol Metab 92.2 (2007): 405–13. DOI: 10.1210/JC.2006-1864
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Т.М. Тутченко, О.А. Бурка, І.В. Сідорова, I.Г. Ноговська, І.М. Маринчина, Н.М. Щербатєй
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.